Article Details
Retrieved on: 2023-12-29 21:24:34
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Sutro Biopharma (NASDAQ:STRO) was able to report positive findings from its phase 1 dose expansion study using luveltamab tazevibulin (STRO-002) for ...
Article found on: seekingalpha.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here